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Extracellular matrixThe endothelin (ET) system consists of two G-protein-coupled receptors (ETA and ETB), three peptide ligands
(ET-1, ET-2 and ET-3), and two activating peptidases (endothelin-converting enzyme-, ECE-1 and ECE-2).
While initially described as a vasoregulatory factor, shown to inﬂuence several cardiovascular diseases, from hy-
pertension to heart failure, ET-1, the predominant form in most cells and tissues, has expanded its pathophysio-
logical relevance by recent evidences implicating this factor in the regulation of ﬁbrosis. In this article, we review
the current knowledge of the role of ET-1 in the development ofﬁbrosis, with particular focus on the regulation of
its biosynthesis and themolecular mechanisms involved in its proﬁbrotic actions.We summarize also the contri-
bution of ET-1 to ﬁbrotic disorders in several organs and tissues. The development and availability of speciﬁc ET
receptor antagonists have greatly stimulated a number of clinical trials in these pathologies that unfortunately
have so far given negative or inconclusive results. This review ﬁnally discusses the circumstances underlying
these disappointing results, as well as provides basic and clinical researchers with arguments to keep exploring
the complex physiology of ET-1 and its therapeutic potential in the process of ﬁbrosis.
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. This is an open access article underchanges in their environment. One of the largest andmost diverse cellu-
lar systems serving to communicate with the external milieu is the su-
perfamily of G-protein coupled receptors (GPCR). GPCR, which are
encoded by more than 800 genes in the human genome constitute a
family of membrane proteins capable of detecting a wide spectrum of
extracellular signals, including photons, ions, small organic molecules
and entire proteins or peptides (for a recent review, see Katritch et al.,
2013). Contemporary to the studies on the identiﬁcation and character-
ization of GPCR by Robert J. Lefkowitz, who received togetherwith Brian
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following the discovery of endothelial-derived relaxing factor by Robert
F. Furchgott in 1980, on identifying new vasoactive factors with
constrictor capabilities (Cerione et al., 1983; Furchgott and Zawadzki,
1980; Masaki, 2004). As a result of this search, a novel peptide named
endothelin (ET) was successfully puriﬁed and characterized in 1988,
and only two years later, two cDNAs encoding the receptors were
cloned and assigned to the family of GPCR (Arai et al., 1990; Sakurai
et al., 1990; Yanagisawa et al., 1988). In humans, it is now clear that
endothelin represents the most potent and long-lasting vasoconstrictor
known, 100 times more potent than noradrenaline, coincidentally the
ligand of the ﬁrst GPCR described by R.J. Lefkowitz (Luscher and
Barton, 2000). The result of this fruitful investigationwas the character-
ization of the endothelin system, consisting of two GPCR (ETA or EDNRA
and ETB or EDNRB), three peptide ligands (ET-1, ET-2 and ET-3), and
two activating peptidases (endothelin-converting enzyme-, ECE-1 and
ECE-2) (Miyauchi and Masaki, 1999). In relation with its ﬁrst described
vasoregulatory role, ET system has been shown to inﬂuence several
cardiovascular diseases, including chronic and ischemic heart failure,
systemic and pulmonary hypertension, atherosclerosis, chronic renal
failure and cerebrovascular disease, and beyond the cardiovascular sys-
tem, the early development of the neural crest and, thus, the formation
of organs (Kedzierski and Yanagisawa, 2001; Rodriguez-Pascual et al.,
2011).
One step forward in the investigation of the pathophysiological role
of the ET system was the realization that signiﬁcantly high levels of
ET-1, the predominant isoform inmost cells and tissues, are persistently
observed in a number of ﬁbrotic diseases (Kawaguchi et al., 1994;
Shi-Wen et al., 2006). This review summarizes the current knowledge
of the role of ET-1 in the development of ﬁbrosis, with particular em-
phasis in the regulation of the biosynthesis of ET-1 in the ﬁbrotic milieu,
the molecular mechanisms described to be involved in its proﬁbrotic
actions, and the contribution of ET-1 to ﬁbrotic disorders in several
organs and tissues.
General concepts on ﬁbrosis: where and how the endothelin
system acts
Over recent years, our understanding of the functions of the
extracellular matrix (ECM) has evolved from the traditional concept of
a static “glue” holding cells into tissues to the more sophisticated one
of a dynamic biomaterial that provides strength and elasticity, as well
as points of interactions with cell surface receptors, and availability of
growth factors. Proper formation and organization of the ECM is essen-
tial for cell and tissue homeostasis. Matrix-related diseases arise from
both defects in the properties of ECM components, as occurs in congen-
ital diseases such as Marfan syndrome and Ehlers–Danlos syndrome, as
well as in conditions characterized with an excess of production and
deposition of ECM components. This excess, generally termed as ﬁbro-
sis, is a pathophysiological circumstance that is common to a number
of chronic diseases including idiopathic pulmonary ﬁbrosis, liver
cirrhosis, systemic sclerosis and nephrosclerosis as well as several
cardiac diseases (Bateman et al., 2009; Varga et al., 2005).
The ﬁbrotic process is the result of an aberrant response to injury.
The immediate response to an insult is the activation of a complex
system of cellular responses whose ultimate goal is the fast and efﬁcient
repair of the tissue. The physiological response of tissues to damage is
very complex and displays context-speciﬁc features. However, there are
a number of events that are common to different tissues, and to awide va-
riety of causative agents (Wynn, 2007). Essentially, theprocess progresses
through 3well-established steps: 1) an initial phase of injury, 2) a second
phase characterized by inﬂammation, and3) a remodeling step,which in-
cludes synthesis and deposition of ECM components by myoﬁbroblasts.
These cells share many characteristics with smooth muscle cells, includ-
ing theirmorphology and contractile capacity, are located at sites of active
ﬁbrosis and are responsible for the synthesis and deposition of ECMproteins (Gabbiani, 2003; Hinz, 2010). Myoﬁbroblasts have been shown
to be able to derive from several cell types including resident ﬁbroblasts,
circulating ﬁbrocytes, epithelial/endothelial cells undergoing epithelial/
endothelial-to-mesenchymal transition, EMT/EndoMT, vascular pericytes
or hepatic stellate cells (Wynn, 2008). ET-1 has been able to promote the
induction of the myoﬁbroblast phenotype in these cell types (Fig. 1). For
example, resident ﬁbroblasts have been shown to transdifferentiate to
myoﬁbroblasts in response to ET-1 in several tissues, including the lung,
heart and skin (Lagares et al., 2012a, 2012b, 2010; Nishida et al., 2007).
Additionally, ET-1 has been also described to promote EMT/EndoMT in
epithelial/endothelial cells as a source of myoﬁbroblasts in the ﬁbrotic
mileau (Jain et al., 2007; Piera-Velazquez et al., 2011; Sun et al., 1997).
Bone marrow derived monocytes have also been reported to undergo
myoﬁbroblast transition in response to ET-1 (Binai et al., 2012). In the
context of liver ﬁbrosis, hepatic stellate cells have been shown to trans-
form into ﬁbrotic ﬁbroblasts by the action of ET-1 (He et al., 2013; Zhan
and Rockey, 2011). Finally, vascular pericytes, contractile cells wrapping
around endothelial cells within capillaries in the microvasculature, have
been recently proposed to play an important role in tissue ﬁbrosis giving
rise to myoﬁbroblasts in response to several factors, including ET-1
(Fligny and Dufﬁeld, 2013; Simonson and Ismail-Beigi, 2011).
The acquisition of the myoﬁbroblast phenotype endows the ﬁbrotic
cell with several capabilities, including enhanced contractility, migra-
tion and synthesis and deposition of ECM components. To this respect,
early work done before the extent of role of ET-1 in the onset of ﬁbrosis
was even recognized; described the capacity of ET-1 to enhance the
expression of collagen isoforms in several cells and tissues, including
cardiac ﬁbroblasts and smooth muscle cells, among others (Guarda
et al., 1993; Mansoor et al., 1995; Rizvi et al., 1996). These observations
have been later corroborated in studies performed in heart, skin, lung,
liver or even in the eye within the lamina cribrosa (Ammarguellat
et al., 2001; Guo et al., 2004; Haﬁzi et al., 2004; Horstmeyer et al.,
2005; Nishida et al., 2007; Rao et al., 2008; Shi-wen et al., 2007;
Simonson and Ismail-Beigi, 2011; Xu et al., 1998).
In a physiological wound healing response, the cellular and acellular
components of the scar are eliminated and the ﬁbrotic deposition
becomes replaced by regenerated tissue. Myoﬁbroblast elimination by
apoptosis seems to play a key role in this resolution phase, and failure
in this process seems to contribute to the development of ﬁbrosis (Kis
et al., 2011). To this respect, ET-1 has been described to promote
myoﬁbroblast resistance to apoptosis and therefore contribute to the
persistence of the ﬁbrotic response (Horowitz et al., 2012).
Regulation of the expression of ET-1 in ﬁbrosis
Having described that ET-1 is able to promote the induction of the
myoﬁbroblast differentiation, a process associated to enhanced synthesis
and deposition of ECMcomponents, it is pertinent to discuss the cells con-
tributing to its biosynthesis and how it is regulated. By the action of a
number of factors discussed below, different cell types involved in the ﬁ-
brotic process, including lung, skin or cardiacﬁbroblasts or hepatic stellate
cells, among others, have been described to generate signiﬁcant amounts
of bioactive ET-1 (Abraham et al., 1997; Katwa, 2003; Rockey et al., 1998;
Shi-Wen et al., 2004; Shi-Wen et al., 2001). Nevertheless, most of the
knowledge we have today about themechanisms controlling the expres-
sion of ET-1 comes from research studies performed with endothelial
cells, its most important biological source (Rodriguez-Pascual et al.,
2011). Numerous experimental evidences implicate mRNA transcription
as a major control of ET-1 biosynthesis. Several transcriptional factors in-
cluding activator protein-1 (AP-1), GATA, Smad or hypoxia-inducible
factor-1 (HIF-1), have been described to interact with speciﬁc genomic
regions within the ET-1 gene promoter, thereby acting as mediators for
the action of different biological and pharmacological factors (Inoue
et al., 1989; Rodriguez-Pascual et al., 2011). Transforming growth
factor-β (TGF-β), thrombin, bradykinin, angiotensin II, interferon-γ
(IFN-γ), the glucocorticoids or the hypoxia upregulates ET-1 mRNA
Fig. 1. Main pathways for ET-1-induced myoﬁbroblast differentiation. Based on a number of reports (references included), ET-1 has been shown to promote the induction of the
myoﬁbroblast phenotype from resident ﬁbroblasts, from epithelial/endothelial cells via EMT/EndoMT, from hepatic stellate cells, from circulating bone marrow-derived monocytes
(ﬁbrocytes), and from vascular pericytes.
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oxide, or pharmacological agents such as statins downregulate them
(Miyauchi andMasaki, 1999; Stowet al., 2010). Someof thesemodulators
are particularly interesting in the context of the ﬁbrotic process. Thus,
angiotensin II and the hypoxia, two conditions described to promote the
accumulation of ECM components in several cells and tissues, have been
shown to increase ET-1 expression through activation of AP-1 and
HIF-1, respectively (Ahmedat et al., 2013; Hieda and Gomez-Sanchez,
1990; Hu et al., 1998; Ikeda et al., 2000; Kourembanas et al., 1991). TGF-
β, which is considered a princepsmediator in the development of ﬁbrosis
in a wide variety of tissues, has been also reported to be one of the most
potent regulators of ET-1 levels in endothelial and non-endothelial cells,
this action occurring through activation of AP-1 and Smad transcription
factors (Biernacka et al., 2011; Kurihara et al., 1989; Rodriguez-Pascual
et al., 2003; Ruiz-Ortega et al., 2007). In fact, TGF-β-mediated ET-1 release
has been associated to the ﬁbrotic response observed in scleroderma
(SSc) ﬁbroblasts, and in the context of skin and lung ﬁbrosis (Ahmedat
et al., 2013; Kawaguchi et al., 1994; Lagares et al., 2010; Shi-Wen et al.,
2006). Additional factors or signaling pathways have been also reported
to modulate ET-1 expression in ﬁbrosis. Thus, tumor necrosis factor-α
(TNF-α) has been shown to increase ET-1 levels in hepatic stellate cells
during hepatic wound healing (Zhan and Rockey, 2011). Endoplasmic
reticulum (ER) stress and activation of the ATF4 transcription factor
have been reported to promote signiﬁcant increases in ET-1 expression
in vascular endothelial cells from HLA-B35-expressing SSc patients
(Lenna et al., 2013). Common to these ﬁndings is the activation of the
AP-1 member c-Jun and further enhancement of ET-1 transcription. In
fact, as extensively reported in endothelial cells, AP-1 transcription factor
plays a central role in the control of constitutive and regulated transcrip-
tion of the ET-1 gene, coordinating transcriptional responses to GATA-2,
HIF-1 and Smad transcription factors (Kawana et al., 1995; Rodriguez-
Pascual et al., 2004; Yamashita et al., 2001).
ET-1 expression is also subject of post-transcriptional regulation at
the level ofmRNA stability. ET-1mRNAhas been shown to be highly un-
stable (estimated half-life of 15 min), and speciﬁc adenine and uridine-rich elements (ARE) in the 3′-untranslated region (3′-UTR) seem to be
responsible for transcript lability (Reimunde et al., 2005). Within this
context, several recent reports have described regulatory effects of
particular microRNA (miRNA) on ET-1 expression. Thus, miR-155 and
miR-199 have been shown to downregulate ET-1 levels in liver sinusoi-
dal endothelial cells, andmiR-1was reported to control ET-1 expression
in hepatoma cells (Li et al., 2012; Yeligar et al., 2009). Whether these
miRNA-mediated actions on ET-1 occur in a ﬁbrotic milieu and are
therefore of pathophysiological relevance, and also, whether a unifying
mechanism exists to integrate ARE- andmiRNA-mediated effects for the
control of ET-1 expression, are not yet fully elucidated.
Bioactive ET-1 peptide is also regulated at the level of processing by
endothelin-converting enzymes (ECE). In fact, elevated levels of ECE-1,
and subsequently of ET-1, have been observed in idiopathic pulmonary
ﬁbrosis (IPF) patients, and mouse models displaying null or reduced
activity or ECE-1 are resistant to develop ﬁbrosis in the lung or heart
(Hartopo et al., 2013; Kalk et al., 2011; Saleh et al., 1997).
Molecular and cellularmechanisms regulating ET-1 induced ﬁbrosis
Biological actions of ET-1 involve necessarily the activation of speciﬁc
ETA and/or ETB receptors. Formally speaking these receptors belong to
the rhodopsin A group of GPCR, subfamily A7, and are coupled to Gq,
G11, Gs and Gi2, suggesting that endothelin receptors may simultaneously
stimulatemultiple effectors via several types of G protein, including phos-
pholipase A2, C and D, aswell asmembrane and cytosolic protein kinases.
This complexity together with the fact that most cells can coexpress both
receptors, make rather difﬁcult to predict the mechanism/s involved in
the speciﬁc actions of ET-1 on a particular cell type. Nevertheless, recent
experimental evidences indicate the involvement of particular cell signal-
ing components in ET-1-induced ﬁbrosis (Fig. 2). Thus, mitogen-activated
protein kinases (MAPK) JNK and ERK, known to activate AP-1 transcrip-
tion factor, have been reported to mediate the induction by ET-1 of a
matrix-associated genetic program characterized by the expression of
collagen isoforms, as well as of contractile proteins involved in enhanced
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et al., 2012a, 2010; Shi-wen et al., 2007, 2006; Xu et al., 2004). Upstream
MAPK, signaling components of the cell adhesion machinery, focal adhe-
sion kinase (FAK) and integrin-linked kinase (ILK), have been described
to participate in ET-1-mediated proﬁbrotic actions (Horowitz et al.,
2012; Kennedy et al., 2008; Lagares et al., 2012a, 2012b; Shaﬁei and
Rockey, 2012). Interestingly, both proteins are activated by integrin-
mediated signals from the ECM, indicating that coordinated signals
coming from soluble factors and also from the environment cooperate
to regulate ﬁbrosis. A third set of signaling components is implicated
in ET-1-induced tissue ﬁbrosis. The activation of rac/Rho and
phosphatidylinositide 3-kinase(PI3K)/Akt has been also shown to partic-
ipate in the proﬁbrotic actions of ET-1 (Horowitz et al., 2012; Rodriguez-
Vita et al., 2005; Shaﬁei and Rockey, 2012; Shi-Wen et al., 2004). To add
an extra level of complexity, ET-1 has been also reported to upregulate
the expression of other proﬁbrotic factors, such as connective tissue
growth factor (CCN2/CTGF) or even TGF-β, actually making the ﬁbrotic
response the result of a networkpromoting tissue repair andﬁbrogenesis
(Alvarez et al., 2011; Rodriguez-Vita et al., 2005; Shi-wen et al., 2007).
In addition to characterize the molecular pathways through which
ET receptors drive ET-activated signals, the subtype of receptor, either
ETA or ETB, should be taken into consideration, particularly at those
scenarios where a clinical translation is pursued, and therefore, the
use of a speciﬁc antagonist matters. To this respect, there exists a gener-
al consensus to favor the use of dual ETA/ETB blockers, rather than spe-
ciﬁc ones, biased by the fact that the only antagonist clinically approved
so far belongs to the dual category, together with observations describ-
ing changes in ETA/ETB ratio in pathological contexts and the existence
of ETA/ETB heterodimers (Gregan et al., 2004; Möller et al., 1999). Nev-
ertheless, the potential beneﬁt of selective versus dual antagonism
should be experimental and clinically demonstrated in every particular
model or disease.Fig. 2. Schematic diagram showing the signaling mechanisms contributing to the proﬁbrotic ac
has been shown to activate FAK and ILK, cell adhesion protein kinases known to receive inﬂu
kinases, JNK and ERK, and subsequent AP-1 transcription factor are responsible for the induction
lagen isoforms, as well as of contractile proteins, such asα-smoothmuscle actin (α-SMA). This
cell migration and ECM contraction, both being features of myoﬁbroblast differentiation and ﬁb
several reports have also implicated rac/Rho and PI3K/Akt in ET-1-induced ﬁbrosis.Contribution of ET-1 to ﬁbrosis and ﬁbrotic disorders
As mentioned above, ET-1 has been associated to the development
of ﬁbrosis in different cell and tissue contexts. Here we summarize the
current knowledge of the proﬁbrotic action of ET-1 as classiﬁed by
organ or tissue, together with the most signiﬁcant clinical trials per-
formed to test the therapeutic potential of targeting the ET system in pa-
thologies affecting these tissues, as viewed from a ﬁbrotic perspective.
Lung
Several lines of evidence implicate ET-1 as a mediator in the devel-
opment of excessive scarring and ﬁbrosis in the lung. Thus, plasma
ET-1 levels have been found to be elevated in patients with IPF, and
bronchoalveolar lavage ﬂuids from SSc and IPF patients have been
shown to present also increased ET-1 amounts (Abraham et al., 1997;
Odoux et al., 1997; Uguccioni et al., 1995). Additionally, elevated ex-
pression levels of ET-1 and ET receptors have been reported in lung bi-
opsy samples from SSc patients compared with tissues from control
donors (Abraham et al., 1997). In fact, ET-1 was reported to play a role
in this pathological context as ﬁbroblasts isolated from lungs of SSc
patients showed enhanced ET-1 expression and the expression of
myoﬁbroblast markers or proﬁbrotic factors could be reduced by antag-
onizing ET-1 signaling (Shi-Wen et al., 2004). Reinforcing this hypothe-
sis, data from bleomycin-induced lung ﬁbrosis models in mice or rats
have shown increased ET-1 immunoreactivity in airway epithelium
and inﬁltratingmacrophages, as well as a signiﬁcant reduction in the ﬁ-
brotic score in animals pretreatedwith endothelin receptor antagonists,
and gene transfer of ET-1 in murine lungs induced a proﬁbrotic re-
sponse (Lagares et al., 2012b; Park et al., 1997). Based on this knowl-
edge, ET-1 signaling emerged as a potential target for pharmacological
intervention in the treatment of ﬁbrosis in IPF and SSc. The ﬁrsttions of ET-1 as described in lung or skin ﬁbrosis. ET-1, by acting on ETA and ETB receptors,
ences from the extracellular matrix (ECM) via integrins. Downstream activation of MAP
of a proﬁbrotic genetic programwith expression ofmatrix components, for instance, col-
program, as a whole, induces the net deposition of ECM components and greatly enhances
rosis. While the molecular link between ET receptors and FAK (or ILK) remains unknown,
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program (BUILD-1: Bosentan Use in Interstitial Lung Disease) designed
to test the efﬁcacy of this dual ETA/ETB receptor blocker, currently being
prescribed in pulmonary arterial hypertension, to treat IPF patients
(Table 1) (King et al., 2008). Primary end-point of this study was exer-
cise capacity, whereas secondary objectives were time to death or dis-
ease progression. Bosentan showed no superiority over placebo in the
exercise test (6 minute walk distance), nor in time to death or disease
progression. Nevertheless, a signiﬁcant improvement in the progression
of the disease was observed in a patient subgroup with surgical lung
biopsy-proven IPF. This observation prompted the launching of a second
clinical trial (BUILD-3) restricted to patients with a conﬁdent diagnosis
of IPF as they were considered most likely to respond to treatment.
However, no signiﬁcant difference between treatment groups was ob-
served in the time to disease worsening (the primary end-point)
(King et al., 2011). A more recent clinical trial with macitentan, a dual
blocker developed from the structure of bosentan and showing
increased safety and efﬁcacy in preclinical studies, has also yielded
negative results in patients with IPF or SSc (MUSIC: Macitentan USe in
an Idiopathic pulmonary ﬁbrosis Clinical study) (Raghu et al., 2013b).
Additionally, a clinical study intended to determine whether
ambrisentan, a selective ETA receptor antagonist, was able to reduce
the rate of IPF progression was launched with time to disease progres-
sion as primary end-point (ARTEMIS-IPF). Ambrisentan was not only
unable to halt or slow down the disease worsening, but it was also
linked with an increased risk for IPF progression and respiratory hospi-
talizations (Raghu et al., 2013a). Therefore, while there is a strong con-
sensus within the scientiﬁc community to accept that ET-1 plays a
signiﬁcant role in the development of ﬁbrosis in experimental models
and a number of evidences from studies in patients point towards this
pathogenic role, clinical trials so far failed to demonstrated such a role,
therefore questioning the contribution of ET-1 to human pulmonary ﬁ-
brosis. In fact, the nature of the lung disease is complex with inﬂuences
from genetic and environmental factors, and, apart from pirfenidone
acting on TGF-β signaling, no other single factor or signaling pathway
has been proved to be an efﬁcient target for the treatment of lung ﬁbro-
sis (Richeldi and du Bois, 2011).Table 1
Clinical trials investigating the effects of ET receptor antagonists inﬁbrotic (andﬁbrosis-related)
primary end-point/s and results/comments are also included, as well as the trial references.
Trial Agent (type) Primary end-point
Lung
BUILD-1 (King et al., 2008) Bosentan (dual) Exercise capacity (6MWT)
BUILD-3 (King et al., 2011) Bosentan (dual) Time to disease progression
MUSIC (Raghu et al., 2013b) Macitentan (dual) Forced vital capacity
ARTEMIS-IPF (Raghu et al., 2013a) Ambrisentan (ETA) Time to disease progression
Skin
RAPIDS-1 (Korn et al., 2004) Bosentan (dual) Numbers of new digital ulcer
RAPIDS-2 (Matucci-Cerinic et al., 2011) Bosentan (dual) Numbers of new digital ulcers
Liver
Tripathi et al. (Tripathi et al., 2006) BQ-788 (ETB) Hemodynamics
Kidney
ASCEND (Mann et al., 2010) Avosentan (ETA) Proteinuria, end stage renal d
ASCEND follow up (Kohan et al., 2011) Avosentan (ETA) Proteinuria
Dhaun et al. (Dhaun et al., 2011) Sitaxsentan (ETA) Proteinuria, blood pressure an
Heart
EARTH (Anand et al., 2004) Darusentan (ETA) Left ventricular remodeling
Prasad et al. (Prasad et al., 2006) Enrasentan (dual) Left ventricular remodeling.Skin
Skin ﬁbrosis occurs in a number of human diseases, such as keloids
and most notably SSc, as a result of an exaggerated wound healing re-
sponse. A number of evidences indicate that ET-1 may be a mediator
in the development of skin ﬁbrosis. The binding of ET-1 has been dem-
onstrated by autoradiography in skin biopsies from SSc patients, sug-
gesting an overall increase in ET receptor expression (Vancheeswaran
et al., 1994). In cell culture models, skin ﬁbroblasts have been described
to synthesize signiﬁcant levels of ET-1 and the activation of ET receptors
induces ECM production and accumulation in a process involving the
cell transformation to a myoﬁbroblast phenotype (Abraham et al.,
1997; Shi-Wen et al., 2004, 2001). In addition, ET receptor blockade
was shown to prevent the ﬁbrotic response in the classical mouse
model of bleomycin-skin ﬁbrosis (Lagares et al., 2010). To this respect,
it is noteworthy to mention that ET receptor antagonists were also
able to prevent TGF-β-induced myoﬁbroblast differentiation and ﬁbro-
sis, therefore indicating that reciprocal regulation of TGF-β and ET-1
occurs inwound healing and skin ﬁbrosis (Lagares et al., 2010). Transla-
tion of these experimental evidences to the clinical setting has focused
on themost evident skinmanifestations of SSc disease, the digital ulcers
(DU) and the Raynaud's phenomenon (RP). Case reports of patients
showing improvement in their RP and DU while undergoing therapy
with ET blockers for pulmonary arterial hypertension led to randomized
controlled trials investigating the efﬁcacy of these agents for the treat-
ment of RP and DU in patients with SSc. These observations paved the
initiation of open-label studies and, later on, large randomized clinical
trials. RAPIDS-1 and -2 (Randomized Placebo-controlled Investigation
of Digital ulcers in Scleroderma) studies were performed to test the ef-
ﬁcacy of bosentan in DU in SSc patients. Although both studies were
donewith an interval of seven years, they reached the same conclusion:
bosentan was efﬁcacious in preventing the formation of new DU, but it
did not reduce the numbers of pre-existing ones (Korn et al., 2004;
Matucci-Cerinic et al., 2011). In the case of RP, a small-scale placebo-
controlled, double-blind clinical trial evaluating bosentan for the treat-
ment of RP has disappointingly shown no signiﬁcant different with
the control group (Nguyen et al., 2010). Nevertheless, in the contextdiseases, as classiﬁedby organ or tissue. Information about the type of receptor blocker, the
Outcome. Comments
Ineffective. Improvement in 2nd. end-point:
disease progression
Ineffective. Restricted to patients with diagnosed IPF.
Ineffective.
Ineffective. Halted prematurely due to adverse effects.
s Effective in preventing the formation of new ulcers.
. Time to healing. Effective in preventing the formation of new ulcers.
Inefﬁcacious in diminishing time to healing.
Early cirrhosis patients. Incapable of modifying portal hypertension.
isease and death Effective in reducing proteinuria in the short term.
Prematurely halted due to adverse effects.
Kidney disease patients receiving RAS inhibitors.
Effective in reducing proteinuria.
d arterial stiffness Effective in reducing proteinuria, blood pressure
and arterial stiffness.
Ineffective.
Ineffective.
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consideration that DU and RP are particular forms of vasculopathies,
and that the efﬁcacy (or the lack of it) of ET receptor blockers on these
pathological processes have been attributed to a vascular effect, rather
than due to a broader anti-ﬁbrotic action (Steen et al., 2009). Further ex-
perimental and clinical studies are needed to conclude whether the
blockade of ET signaling may become an effective therapeutic tool for
the treatment of skin ﬁbrosis in a more general context.
Liver
Damage to the liver, as occurs under chronic alcoholic ingestion,
viral infection or mechanical bile duct obstruction, among other patho-
logical conditions, induces a ﬁbrogenic response intended to maintain
organ integrity when extensive necrosis or apoptosis exists. Upon
prolonged injury, ﬁbrosis can progress towards excessive scarring and
organ failure, as in liver cirrhosis (Friedman, 2008). Activation of hepatic
stellate cells remains a central event in liver ﬁbrosis, though there exist
solid evidences supporting additional sources of matrix-producing cells
including bone marrow-derived circulating cells, portal ﬁbroblasts, and
even epithelial–mesenchymal transition from both hepatocytes and
cholangiocytes. ET-1 has been consistently reported to be produced by
the liver, shifting the cell source of its biosynthesis from sinusoidal en-
dothelial cells to stellate cells during liver injury (Rockey et al., 1998).
In fact, ET-1 action on stellate cells is associated with enhanced prolifer-
ation, cell spreading, contractility, and also ﬁbrogenesis, all features of
the activated (myoﬁbroblast-like) phenotype (Khimji and Rockey,
2011). Further, inhibition of ET signaling with ET receptor antagonists
reduces the hepatic ﬁbrogenic response in liver disease experimental
models (Feng et al., 2009; Rockey and Chung, 1996). These preclinical
studies should have indeed encouraged the testing of ET receptor
blockers in cirrhosis patients. However, early clinical studies evaluating
their efﬁcacy to treat pulmonary arterial hypertension soon revealed a
signiﬁcant hepatotoxicity, an observation that has hampered the precise
analysis of their effect in liver disease (Humbert et al., 2007). Neverthe-
less, a very few studies in the context of cirrhosis have been done, such
as the one testing speciﬁc ETA and ETB antagonists on hemodynamic ef-
fects in early cirrhosis patients (Tripathi et al., 2006). It is clear that in
this particular pathological context, new molecules displaying less or
no liver toxicity should be developed and tested in clinical studies,
looking not only at hemodynamics but also directly at ﬁbrotic effects
by using, for instance, FibroScan® (Sandrin et al., 2003).
Kidney
The kidney is a complex organ in which functionality depends on a
number of different cell types. The glomerulus, the functional ﬁltration
unit of the kidney, is composed of two cell types, the fenestrated endo-
thelial cells and the podocytes, separated by the glomerular basement
membrane, essentially a collagen IV-based barrier. Additionally,
supporting the glomerular capillaries are specialized pericytes known
as mesangial cells, a contractile cell type with the ability to produce
and deposit ECM components. Fluid ﬁltered through the glomerulus is
collected in the renal tubule, a duct divided in different functional por-
tions in which epithelial cells play an important role in urine formation.
Whether started as glomerular, tubular or renovascular damage, insults
to the kidney, such as toxins, ischemia, viral or bacterial infection, even-
tually converges into common renal histological and functional alter-
ations affecting most renal structures, which lead to progressive and
generalized ﬁbrosis and glomerulosclerosis, both conditions character-
ized by enhanced ECM deposition. The origin of myoﬁbroblasts in the
kidney has been a matter of intense debate and remains somewhat
controversial. Until very recently, it was widely thought that injured
epithelial cells served as a primary source of myoﬁbroblasts through
an EMT process, an assumption based on the proclivity of epithelial
cells to acquire a mesenchymal phenotype in vitro (Ivanova et al.,2008). However, recent research applying state-of-art fate mapping
methodologies have revealed that pericytes and resident ﬁbroblasts
are themajor, if not the only, source of myoﬁbroblasts in animalmodels
of chronic kidney disease (Campanholle et al., 2013).
ET-1 has been described to be an important factor in renal patho-
physiology, and it is reported to inﬂuence different cell types. For exam-
ple, podocytes have been shown to express ET-1 and ET receptors, and
also respond to increased ET-1 levels with cytoskeletal remodeling
and enhanced protein permeability (Fligny et al., 2011; Morigi et al.,
2006). Glomerular endothelial cells are probably the main source of
ET-1 within the glomerulus, and this production is increased in chronic
kidney disease (Herman et al., 1998; Lehrke et al., 2001).Mesangial cells
produce also signiﬁcant amounts of ET-1, and interestingly, they syn-
thesize and deposit more matrix upon stimulation with ET-1 (Mishra
et al., 2003; Sakamoto et al., 1990). As a vasoconstrictor factor, it has
been long appreciated that ET-1 contributes signiﬁcantly to the control
of blood pressure, a role implicating renal ET-1 production. Neverthe-
less, increasing experimental evidences indicate that the actions of
ET-1 linking to renal disease aremostly independent of hypertensive ef-
fects (Dhaun et al., 2012). In the particular case of ﬁbrosis, overexpres-
sion of ET-1 in transgenic mice has been reported to promote collagen
deposition with subsequent loss of kidney function, an action not in-
volving hemodynamical effects (Hocher et al., 1997). In fact, ET receptor
antagonists have been shown to have beneﬁcial effects in several
models of renal disease, including hypertensive or diabetic nephropa-
thy, and glomerulonephritis, with signiﬁcant reduction in the accumu-
lation of matrix components (Dhaun et al., 2012). Again, in spite of
these promising observations, clinical studies are scarce and inconclu-
sive. For example, the ASCEND trial evaluating the effect of avosentan,
an ETA receptor antagonist, on diabetic nephropathy was prematurely
terminated due to adverse cardiovascular effects, likely being attributed
to signiﬁcant ﬂuid retention, although partial results showed a signiﬁ-
cant reduction in albuminuria (Mann et al., 2010). A follow-up study
with lower doses of avosentan in patients receiving renin–angioten-
sin system inhibitors, as well as a recent trial using sitaxsentan (spe-
ciﬁc ETA), showed indeed beneﬁcial effects on proteinuria, while
lacking moderate detrimental actions (Dhaun et al., 2011; Kohan
et al., 2011). Deﬁnitely more clinical studies are needed to clarify
the potential beneﬁt of ET blockade in chronic kidney disease, not
only looking to proteinuria or blood pressure, but also to the extent
of renal ﬁbrosis.
Heart and vasculature
As mentioned above, vascular alterations such as RP or DU precede
the development of certain ﬁbrotic disorders, such as SSc or IPF
(Lagares et al., 2012a; Trojanowska, 2010). Early vasculopathy in these
diseases is frequently associated with signiﬁcant vascular ﬁbrosis
(seen as reduced lumen diameter and arterial wall thickening), which
somehow is transmitted to the surrounding tissue, lung or skin. There-
fore, the vasculature is a major player in the development of ﬁbrosis,
supporting the differentiation of matrix-producing myoﬁbroblasts,
either by endothelial-to-mesenchymal transition or from perycites.
Taking this into consideration and also the fact that the main source
(and likely also the main target) of ET-1 is the vascular system, it is
not surprising that ET-1 system inﬂuences the synthesis and deposition
of matrix components in the vasculature. Thus, mice genetically modi-
ﬁed to overexpress ET-1 in the endothelium show enhanced ECMdepo-
sition, resulting in structural remodeling of small arteries, an action that
occurswithout elevation of blood pressure, but can be greatly potentiat-
ed by salt loading-induced hypertension (Amiri et al., 2010; Amiri et al.,
2004). In agreement with these results, the development of cardiac
ﬁbrosis and hypertrophy in mouse models is impaired in mice with
vascular endothelial cell-speciﬁc ET-1 deﬁciency (Adiarto et al., 2012).
Cardiac ﬁbrosis as a consequence of an ischemic injury or upon
pressure/volume overload is a pathological event of important clinical
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phy, ET-1 has been shown to induce matrix protein synthesis as well as
proliferation in cardiac ﬁbroblasts, both being crucial events in the
ﬁbrotic heart response (Guarda et al., 1993; Piacentini et al., 2000). ET
antagonism has been reported to attenuate myocardial ﬁbrosis in ani-
malmodels of heart disease (Ammarguellat et al., 2001). Administration
of bosentan to patients with severe heart failure resulted in hemody-
namic and cardiac beneﬁts (Sutsch et al., 1998). These ﬁndings have
stimulated a number of randomized controlled clinical trials examining
the effects of ET receptor antagonists on coronary artery disease and
heart failure that have not given a clear positive result, and in many
studies even a harmful effect, in most cases attributed to enhanced
ﬂuid retention. The list of trials is long (for a recent review, see Kohan
et al., 2012) and its detailed description is beyond the scope of this re-
view article. Focused only on those assays having left ventricular (LV)
remodeling as primary end-point, assuming that LV remodeling might
be considered as an index of ﬁbrosis progression, which is not totally
true as cardiomyocyte hypertrophy importantly contributes to this
phenomenon, the administration of darusentan as in the EARTH
(Endothelin A Receptor antagonist Trial in Heart failure) study, or of
enrasentan (a dual ETA/ETB antagonist) did not show any favorable ef-
fects, despite improved hemodynamics (Anand et al., 2004; Jugdutt
et al., 2013; Prasad et al., 2006). Again, the great expectations and the
tremendous effort on preclinical and clinical trials have been without
reward (Kolettis et al., 2013).
Conclusions and future perspectives
Accumulating evidence from cellular and animal data indicate that
ET-1 is an important contributor of tissue ﬁbrosis. Human studies also
suggest that ET-1 may also be relevant in ﬁbrotic disorders, such as
SSc and IPF. Thus, ET-1 emerged as a potential target for pharmacologi-
cal intervention in the treatment of ﬁbrosis. Nevertheless, the results of
a number of clinical trials examining the efﬁcacy of ET receptor antago-
nists in the context of these diseases did not achieve the primary objec-
tives, a reduction in morbidity/mortality, although they showed a
tendency towards those goals (King, 2008). Only bosentan has been ap-
proved for use, and in this case, only for one particular case: digital ul-
ceration associated to SSc. Signiﬁcant liver toxicity or ﬂuid retention
has hampered the development of ET receptor antagonists as effective
therapeutic agents. Additionally, other factors already mentioned in
this review, such as the complex nature of the ﬁbrotic disease, involving
multiple factors, or alternative plausible explanations, such as the estab-
lishment of no-return points in the onset of ﬁbrosis beyond which the
pharmacological intervention offers little or no beneﬁcial effects,
might also contribute to the lack of positive results. This should not dis-
courage current and future investigation in the ﬁeld. Reﬁnement in the
toxicological proﬁle of ET blockers, together with a careful selection of
dosage and patient recruitment should be implemented in future stud-
ies, as well as the opening of this type of drugs to yet unexplored areas,
such as the ﬁbrotic response upon trabeculectomy in glaucomatous
eyes (Georgoulas et al., 2008). Nevertheless, in any circumstance, an
increasing research effort must deﬁnitely be directed to the dissection
of the complex physiology of the ET-1 system by using both in vitro
and in vivo approaches, particularly in the initial stages of the ﬁbrotic
response.
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